Molecular biomarkers in cancer
VK Sarhadi, G Armengol - Biomolecules, 2022 - mdpi.com
Molecular cancer biomarkers are any measurable molecular indicator of risk of cancer,
occurrence of cancer, or patient outcome. They may include germline or somatic genetic …
occurrence of cancer, or patient outcome. They may include germline or somatic genetic …
FLT3 Mutations in Acute Myeloid Leukemia: Key Concepts and Emerging Controversies
VE Kennedy, CC Smith - Frontiers in Oncology, 2020 - frontiersin.org
The FLT3 receptor is overexpressed on the majority of acute myeloid leukemia (AML) blasts.
Mutations in FLT3 are the most common genetic alteration in AML, identified in …
Mutations in FLT3 are the most common genetic alteration in AML, identified in …
TP53 abnormalities correlate with immune infiltration and associate with response to flotetuzumab immunotherapy in AML
Somatic TP53 mutations and 17p deletions with genomic loss of TP53 occur in 37% to 46%
of acute myeloid leukemia (AML) with adverse-risk cytogenetics and correlate with primary …
of acute myeloid leukemia (AML) with adverse-risk cytogenetics and correlate with primary …
Comparison and validation of the 2022 European LeukemiaNet guidelines in acute myeloid leukemia
CA Lachowiez, N Long, J Saultz, A Gandhi… - Blood …, 2023 - ashpublications.org
Risk stratification in acute myeloid leukemia (AML) remains principle in survival
prognostication and treatment selection. The 2022 European LeukemiaNet (ELN) …
prognostication and treatment selection. The 2022 European LeukemiaNet (ELN) …
Validation and refinement of the 2022 European LeukemiaNet genetic risk stratification of acute myeloid leukemia
C Rausch, M Rothenberg-Thurley, A Dufour… - Leukemia, 2023 - nature.com
Abstract The revised 2022 European LeukemiaNet (ELN) AML risk stratification system
requires validation in large, homogeneously treated cohorts. We studied 1118 newly …
requires validation in large, homogeneously treated cohorts. We studied 1118 newly …
Outcome prediction by the 2022 European LeukemiaNet genetic-risk classification for adults with acute myeloid leukemia: an Alliance study
Abstract Recently, the European LeukemiaNet (ELN) revised its genetic-risk classification of
acute myeloid leukemia (AML). We categorized 1637 adults with AML treated with …
acute myeloid leukemia (AML). We categorized 1637 adults with AML treated with …
Venetoclax and hypomethylating agents in acute myeloid leukemia: Mayo Clinic series on 86 patients
E Morsia, K McCullough, M Joshi… - American journal of …, 2020 - Wiley Online Library
Venetoclax and hypomethylating agent (HMA) combination therapy is FDA‐approved for
elderly or unfit acute myeloid leukemia (AML) patients unable to withstand intensive …
elderly or unfit acute myeloid leukemia (AML) patients unable to withstand intensive …
WT1 and PRAME RNA-loaded dendritic cell vaccine as maintenance therapy in de novo AML after intensive induction chemotherapy
Y Fløisand, M Remberger, I Bigalke, D Josefsen… - Leukemia, 2023 - nature.com
Intensive induction chemotherapy achieves complete remissions (CR) in> 60% of patients
with acute myeloid leukemia (AML) but overall survival (OS) is poor for relapsing patients not …
with acute myeloid leukemia (AML) but overall survival (OS) is poor for relapsing patients not …
Sex-associated differences in frequencies and prognostic impact of recurrent genetic alterations in adult acute myeloid leukemia (Alliance, AMLCG)
Clinical outcome of patients with acute myeloid leukemia (AML) is associated with
demographic and genetic features. Although the associations of acquired genetic alterations …
demographic and genetic features. Although the associations of acquired genetic alterations …
TP53 Mutations in Acute Myeloid Leukemia: Still a Daunting Challenge?
TP53 is a key tumor suppressor gene with protean functions associated with preservation of
genomic balance, including regulation of cellular senescence, apoptotic pathways …
genomic balance, including regulation of cellular senescence, apoptotic pathways …